First-in-human study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of VTX-PID in healthy male volunteers

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-503892-83-00

Acronym

VTX-PID_CLN_001

Enrollment

Registered

2023-09-28

Start date

2024-12-27

Completion date

2025-06-28

Last updated

2025-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy volunteers with circulating Neutralising antibodies (NAbs) against AAV

None listed

Sex/Gender

Male

Age

18 Years to 64 Years

Germany

None listed

Source: EU CTIS · Data processed: May 22, 2026